Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Review Gets Under Way For Lumasiran And Lonafarnib

Alnylam And Eiger Will Have Their Products Fast-Tracked

Executive Summary

The European Medicines Agency produces a monthly list of the marketing authorizations that are under review at the agency. The latest list contains just two new entries.

You may also be interested in...



UK Allows Early Access To Alnylam’s Lumasiran For Ultra-Rare Disorder

UK patients diagnosed with primary hyperoxaluria Type 1 can now be prescribed lumasiran, which is still being reviewed for EU-wide approval. Patients in the US, Germany and other EU countries can also get the drug under early access schemes.

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

EU Accelerated Assessment Tracker

Alnylam and Eiger join the select group of companies whose products have been granted fast-track status at the European Medicines Agency

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel